INOVIO Announces Proposed Public Offering

Inovio (Nasdaq: INO) announced a proposed underwritten public offering of common stock and accompanying warrants to purchase common stock, or pre-funded warrants in lieu of common stock.

Rhea-AI Summary

Inovio (Nasdaq: INO) announced a proposed underwritten public offering of common stock and accompanying warrants to purchase common stock, or pre-funded warrants in lieu of common stock. Inovio intends to grant the underwriter a 30-day option to buy up to an additional 15% of the offered shares and/or accompanying warrants on the same terms.

All securities in the proposed offering would be sold by Inovio. The transaction is subject to market conditions, with no assurance on completion, size, or terms. Piper Sandler is acting as sole manager. The securities are being offered under an effective shelf registration statement filed July 2, 2026 and declared effective July 10, 2026.

Positive

• Primary offering – all securities sold by Inovio, so proceeds from any completed deal accrue to the company
• 15% overallotment option provides flexibility to increase the offering size if investor demand supports it
• Effective shelf registration already in place, enabling quicker access to capital markets when terms are finalized

Negative

• Potential dilution to existing shareholders from new common shares and warrants if the offering is completed
• Warrant issuance may create an overhang from additional potential future share issuances
• Outcome uncertainty – offering is subject to market conditions, with no assurance on completion, size, or pricing

News Explained

No offering size or price is committed; if completed, INOVIO’s issuance would dilute existing percentage ownership, while proceeds remain unquantified.

The proposed offering remains conditional and unpriced; if completed, issuing the offered common shares—or shares from exercised pre-funded warrants—would reduce existing holders’ percentage ownership.

Because INOVIO is selling all the securities, the gross sale proceeds would be raised by the company; underwriting fees would reduce net proceeds below the gross amount.

The pre-funded-warrant alternative would convert into shares when exercised, creating another potential source of added shares under the proposed structure.

As of March 31, 2026, INOVIO reported $26,271,650 of cash and equivalents, alongside $11,409,607 of short-term investments; the offering’s undisclosed size prevents a direct liquidity comparison.

The preliminary prospectus supplement is the next document to watch for the offering’s size, price, fees, and warrant terms, while the release leaves completion unresolved; a prospectus supplement states the final terms of a specific offering.

Argus Jul 30 session 72 alerts

-36.92% close to close 18.7x rel. volume Open Argus

Details

Market reaction after proposed public offering: INO -36.92% in the Jul 30 session

-47.5% Trough in 24 hr 48 min

$83.64M Market Cap

In the Jul 30 session, INO declined 36.92%, reflecting a significant negative market reaction. Argus tracked a trough of -47.5% from its starting point during tracking. Our momentum scanner triggered 72 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 18.7x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -36.9% in the session following this news. INOVIO's offering-tagged history averag...

Analysis

The stock dropped -36.9% in the session following this news. INOVIO's offering-tagged history averaged -24.39% across five events. A strong negative reaction would be consistent with that record; this proposed company-led sale has no stated size or terms, while high short positioning remains a sourced volatility risk.

Key Figures

Article date: July 29, 2026 Underwriter option period: 30 days Additional securities option: 15% +2 more

Article date

July 29, 2026

Article dateline

Underwriter option period

30 days

Option to purchase additional shares and/or accompanying warrants

Additional securities option

15%

Maximum additional shares and/or accompanying warrants

Shelf registration filing date

July 2, 2026

Shelf registration statement filed with the SEC

Shelf registration effective date

July 10, 2026

Shelf registration statement declared effective by the SEC

Previous Offering Reports

5 past events · Latest: Apr 02

Same Type 5 events

1. Apr 02

   Offering pricing

   24h Move

   -35.1%

   Priced underwritten offering with common shares, warrants, and expected gross proceeds.

2. Apr 01

   Proposed offering

   24h Move

   -35.1%

   Announced proposed underwritten offering of common stock and accompanying warrants.

3. Nov 11

   Offering pricing

   24h Move

   -7.0%

   Priced public offering of common stock at stated per-share price.

4. Nov 10

   Proposed offering

   24h Move

   -7.0%

   Announced proposed company sale with an underwriter option and shelf registration.

5. Jul 03

   Offering pricing

   24h Move

   -37.9%

   Priced common shares with accompanying warrants and an underwriter option.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, pre-funded warrants, shelf registration statement, prospectus supplement

4 terms

underwritten public offering financial

"intends to offer and sell shares of its common stock and accompanying warrants"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

pre-funded warrants financial

"or pre-funded warrants in lieu thereof"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

shelf registration statement regulatory

"A shelf registration statement relating to the shares of common stock"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

prospectus supplement regulatory

"A preliminary prospectus supplement and accompanying prospectus"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof), in an underwritten public offering. INOVIO intends to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or accompanying warrants in an amount up to 15% of the shares of its common stock and/or accompanying warrants offered in the public offering under the same terms and conditions. All of the securities in the proposed offering will be sold by INOVIO. The proposed offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Piper Sandler is acting as sole manager for the offering.

A shelf registration statement relating to the shares of common stock and accompanying warrants offered in the offering described above was filed with the Securities and Exchange Commission ("SEC") on July 2, 2026 and declared effective by the SEC on July 10, 2026. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by contacting: Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by e-mail at prospectus@psc.com. 

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools.

Forward-Looking Statements

This release contains or may imply "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding INOVIO's anticipated public offering, including the completion of the public offering on the anticipated terms, if at all, and INOVIO's plans to grant the underwriter a 30-day option to purchase additional shares and/or warrants. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in INOVIO's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and in other filings that INOVIO makes with the SEC from time to time. There can be no assurance that any of the forward-looking information provided herein will be proven accurate. These forward-looking statements speak only as of the date hereof and INOVIO undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Contacts

Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Peter Vozzo, ICR Healthcare, 443-213-0505 peter.vozzo@icrhealthcare.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-announces-proposed-public-offering-302838210.html

SOURCE Inovio Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Inovio (NASDAQ: INO) announce on July 29, 2026 about a public offering?

Inovio announced it intends to conduct an underwritten public offering of common stock and accompanying warrants. According to Inovio, all securities would be sold by the company, and the transaction’s completion, size, and final terms remain subject to market conditions.

What securities are included in Inovio’s proposed public offering of INO shares and warrants?

The proposed offering includes shares of common stock and accompanying warrants, or pre-funded warrants instead of common stock. According to Inovio, all securities are part of an underwritten public offering under an effective shelf registration with the SEC filed in July 2026.

What is the 30-day 15% option in Inovio’s July 2026 INO stock offering?

Inovio intends to grant the underwriter a 30-day option to purchase up to 15% additional shares and/or accompanying warrants. According to Inovio, this overallotment option would be on the same terms and conditions as the main offering tranche.

Who is managing Inovio’s proposed public offering of INO common stock and warrants?

Piper Sandler is acting as the sole manager for Inovio’s proposed underwritten public offering. According to Inovio, investors will be able to access the preliminary prospectus supplement and base prospectus through the SEC’s website and by contacting Piper Sandler’s prospectus department.

How can investors obtain the prospectus for Inovio’s July 2026 INO offering?

Investors can access the preliminary prospectus supplement and prospectus on the SEC’s website when filed. According to Inovio, copies may also be requested from Piper Sandler’s prospectus department by mail, telephone, or email using the contact details provided.

Is Inovio’s July 2026 INO stock and warrant offering already completed?

No, the transaction is still a proposed underwritten public offering subject to market conditions. According to Inovio, there is no assurance regarding whether or when the offering will be completed, nor about its actual size or final economic terms.

Under what registration is Inovio’s proposed INO offering being made?

The offering is being made under a shelf registration statement filed July 2, 2026 and declared effective July 10, 2026. According to Inovio, the public sale will occur only by means of a written prospectus and prospectus supplement forming part of this registration.